» Articles » PMID: 23721511

Neem Leaf Extract Induces Cell Death by Apoptosis and Autophagy in B-chronic Lymphocytic Leukemia Cells

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2013 Jun 1
PMID 23721511
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated neem leaf extract (NLE) after a patient with CLL demonstrated disease regression upon taking oral NLE. NLE-mediated apoptosis was examined in peripheral blood mononuclear cells (PBMCs) from 41 patients with CLL. NLE induced a dose-dependent reduction in CLL cell viability with significant apoptosis observed at 0.06% (w/v) by 24 h. Annexin-V staining and poly(ADP-ribose) polymerase 1 (PARP-1) and caspase 3 cleavage were observed after NLE treatment. However, a pan-caspase inhibitor only partially blocked NLE-mediated cell death. NLE also caused loss of mitochondrial outer membrane permeability and nuclear translocation of apoptosis-inducing factor. Furthermore, NLE treatment resulted in LC3-I cleavage. Biochemical analyses revealed that NLE also inhibits Bcl-2 and p53 proteins. In summary, NLE exhibits anti-leukemic properties in patient primary CLL cells and demonstrates clinical efficacy, warranting further investigation as a potential therapy for CLL.

Citing Articles

Analysis of Inhibition Potential of Nimbin and its Analogs against NF-κB Subunits p50 and p65: A Molecular Docking and Molecular Dynamics Study.

Khan A, Singh D, Waidha K, Sisodiya S, Gopinath P, Hussian S Anticancer Agents Med Chem. 2023; 24(4):280-287.

PMID: 37694791 DOI: 10.2174/1871520623666230908101204.


Exploring the role of  (neem) and its active compounds in the regulation of biological pathways: an update on molecular approach.

Sarkar S, Singh R, Bhattacharya G 3 Biotech. 2021; 11(4):178.

PMID: 33927969 PMC: 7981372. DOI: 10.1007/s13205-021-02745-4.


Morphological Assessment of Apoptosis Induced by Nimbolide; A Limonoid from .

Kashif M, Hwang Y, Kim W, Kim G Iran J Pharm Res. 2019; 18(2):846-859.

PMID: 31531067 PMC: 6706709. DOI: 10.22037/ijpr.2019.2391.


Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.

Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M Clin Cancer Res. 2019; 25(13):3974-3985.

PMID: 30940652 PMC: 6744942. DOI: 10.1158/1078-0432.CCR-18-3412.


Waldenstrom macroglobulinemia cells devoid of BTK or CXCR4 mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.

Paulus A, Akhtar S, Yousaf H, Manna A, Paulus S, Bashir Y Blood Cancer J. 2017; 7(5):e565.

PMID: 28548645 PMC: 5518884. DOI: 10.1038/bcj.2017.40.